Innate Pharma (IPHA) Enterprise Value (2017 - 2025)

Innate Pharma has reported Enterprise Value for 9 years, with the latest figure at -$39.9 million in Q4 2025.

• For the quarter ending Q4 2025, Enterprise Value rose 53.73% year-over-year to -$39.9 million; the trailing twelve-month figure through Dec 2025 stood at -$39.9 million (up 53.73% YoY), and the FY2025 full-year result was -$39.9 million, up 53.73% from the prior year.
• Enterprise Value for Q4 2025 stood at -$39.9 million, up from -$67.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$39.9 million in Q4 2025, with the low at -$183.2 million in Q2 2021.
• Historically, Enterprise Value has averaged -$106.0 million across 5 years, with a median of -$101.5 million in 2022.
• Annual changes were most pronounced in 2021 — Enterprise Value soared 99.88% — and 2023, when it gained 3.92%.
• Innate Pharma's Enterprise Value stood at -$137.1 million in 2021, then climbed by 24.47% to -$103.5 million in 2022, then gained by 3.92% to -$99.5 million in 2023, then gained by 13.24% to -$86.3 million in 2024, then soared by 53.73% to -$39.9 million in 2025.
• The last three Enterprise Value figures came in at -$39.9 million (Q4 2025), -$67.9 million (Q2 2025), and -$86.3 million (Q4 2024), per Business Quant data.